Risk-Based Quality Assessment Growing Among ANDA Chemistry Reviews
Executive Summary
The Office of Generic Drugs implemented risk-based quality assessment for some ANDA chemistry reviews in 2013 and found it helped speed up the process and enabled reviewers to better handle the submission volume.
You may also be interested in...
ANDA Avalanche: How Will FDA Deal With The 600 Received This Month?
Experts say one idea may be to borrow some new drug staff to help relieve the pressure; FDA says it will use all available resources.
FDA Envisions Many Regulatory Coalitions Dealing With Globalization Issues
FDA could help create several international coalitions to carry out its new globalization plan, which could allow for issue-specific groups focused on individual pharmaceutical sectors.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.